Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.
Seifert, Karin;
Juhls, Christiane;
Salguero, Francisco J;
Croft, Simon L;
(2015)
Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.
Antimicrobial agents and chemotherapy, 59 (9).
pp. 5819-5823.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00273-15
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Combination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve the treatment of complex manifestations of the disease. We evaluated a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard antileishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.
